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Objective. This study undertook to determine if the presence of
atrial fibrillation in patients with asymptomatic and symptomatic
left ventricular dysfunction was associated with increased mortal-
ity and, if so, whether the increase could be attributed to progres-
sive heart failure or arrhythmic death.
Background. Atrial fibrillation is a common condition in heart
failure with the potential to impact hemodynamics and progres-
sion of left ventricular systolic dysfunction as well as the electro-
physiologic substrate for arrhythmias. The available data do not
conclusively define the effect of atrial fibrillation on prognosis in
heart failure.
Methods. A retrospective analysis of the Studies of Left Ven-
tricular Dysfunction Prevention and Treatment Trials was con-
ducted that compared patients with atrial fibrillation to those in
sinus rhythm at baseline for the risk of all-cause mortality,
progressive pump-failure death and arrhythmic death.
Results. The patients with atrial fibrillation at baseline, com-
pared to those in sinus rhythm, had greater all-cause mortality
(34% vs. 23%, p < 0.001), death attributed to pump-failure (16.7%
vs. 9.4%, p < 0.001) and were more likely to reach the composite
end point of death or hospitalization for heart failure (45% vs.
33%, p < 0.001), but there was no significant difference between
the groups in arrhythmic deaths. After multivariate analysis,
atrial fibrillation remained significantly associated with all-cause
mortality (relative risk [RR] 1.34, 95% confidence interval [CI]
1.12 to 1.62, p 5 0.002), progressive pump-failure death (RR 1.42,
95% CI 1.09 to 1.85, p 5 0.01), the composite end point of death
or hospitalization for heart failure (RR 1.26, 95% CI 1.03 to 1.42,
p 5 0.02), but not arrhythmic death (RR 1.13; 95% CI 0.75 to 1.71;
p 5 0.55).
Conclusions. The presence of atrial fibrillation in patients with
asymptomatic and symptomatic left ventricular systolic dysfunc-
tion is associated with an increased risk for all-cause mortality,
largely explained by an increased risk for pump-failure death.
These data suggest that atrial fibrillation is associated with
progression of left ventricular systolic dysfunction.
(J Am Coll Cardiol 1998;32:695–703)
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Atrial fibrillation is common in patients with heart failure and
is estimated to occur in 15% to 30% of patients during the
course of their disease (1–5). This rhythm is associated with a
variety of potentially deleterious hemodynamic consequences
that might exert a negative influence on prognosis and accel-
erate progression of left ventricular systolic dysfunction in
patients with heart failure. Recent data also suggest that the
irregular sequence of ventricular cycle lengths (R-R intervals)
resulting from atrial fibrillation is associated with adverse
hemodynamic consequences independent of heart rate (6).
Despite the potentially adverse hemodynamic and electro-
physiologic consequences of this common dysrhythmia, the
prognostic implications of atrial fibrillation in heart failure
remain unclear. (1,2,7–11). Therefore, to further study the
influence of atrial fibrillation on survival and progression of
disease in mild to moderate heart failure, we conducted a
retrospective analysis of the Studies of Left Ventricular Dys-
function (SOLVD) Prevention and Treatment Trials to eval-
uate the association of atrial fibrillation with all-cause mortal-
ity, death due to progressive pump failure and arrhythmic
death.
Methods
SOLVD prevention and treatment trial design. The
SOLVD Prevention and Treatment Trials assessed the effect
of angiotensin-converting enzyme inhibition on survival in
patients with heart failure (12–14). A total of 4,228 patients
participated in the Prevention Trial, which consisted mostly of
asymptomatic, New York Heart Association (NYHA) class I
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patients, but approximately one-third of patients in the Pre-
vention Trial were classified with NYHA class II symptoms.
The Treatment Trial randomized a total of 2,569 patients, all
of whom had symptomatic heart failure. In both trials partic-
ipants were required to have a recently documented ejection
fraction #35%. This was assessed by radionuclide angiography
in 68%, two-dimensional echocardiography in 21% and con-
trast angiography in 11% of the participants. There was no
difference in the proportion of patients with atrial fibrillation
compared to sinus rhythm whose qualifying ejection fraction
was assessed by radionuclide angiography (64% vs. 63%, p 5
0.82). All participants were randomized to treatment with
enalapril, at doses of 2.5 to 20 mg/day, or placebo in a
double-blind manner. The primary end point in both trials was
total mortality. Exclusion criteria included: the presence of
active angina pectoris requiring surgical intervention, unstable
angina, myocardial infarction within 1 month of study start,
renal failure (creatinine .2.0 mg%) or severe pulmonary
disease. The average follow-up time, analyzing both trials
together, was 33.4 6 14.3 months.
Data collection and definitions. Data on baseline patient
demographics, past medical conditions and current medication
profiles were obtained for all participants at the time of
enrollment into either of the SOLVD Trials. A baseline
electrocardiogram (ECG) was obtained on each participant at
the time of randomization. For the present analysis, we
identified participants with atrial fibrillation or sinus rhythm
based upon the rhythm present on the prerandomization ECG.
Patients identified with a history of atrial fibrillation but in
sinus rhythm on the baseline ECG were considered to have
sinus rhythm for the purposes of the present analysis. Consid-
ering both the SOLVD Prevention and Treatment Trials, a
total of 280 patients (4.1%) were missing data regarding the
rhythm present on the baseline ECG. These participants are
excluded from the present analysis.
Definition of end points. Causes of death were classified by
blinded review of the circumstances surrounding each death by
the principal investigator at each site. This analysis defines
deaths due to progressive pump failure as those deaths classi-
fied by the SOLVD investigators as due to pump failure as well
as those classified as “arrhythmic with some antecedent wors-
ening heart failure.” We define arrhythmic deaths to include
those deaths classified by the SOLVD investigators as “prob-
able arrhythmia with no antecedent worsening of heart fail-
ure.”
Statistical methods. Age and ejection fraction were ana-
lyzed as continuous variables. The following variables were
analyzed as dichotomous variables, indicating the presence or
absence of the risk factor: diabetes, prior hypertension, prior
myocardial infarction, history of angina, prior stroke and atrial
fibrillation on the prerandomization ECG. Data regarding the
use of medications were based upon each participant’s active
medication profile at the time of randomization into either of
the SOLVD Trials. A participant was considered to be using a
medication if he or she used that medication at the time of
randomization.
Use of the following medications was analyzed as binary
data: anticoagulants, antiplatelet agents, concomitant use of
anticoagulant and antiplatelet agents, randomization to enala-
pril, diuretics, antiarrhythmic drugs and digoxin. The severity
of heart failure symptoms as measured by the NYHA func-
tional class was analyzed as a dichotomous variable, comparing
those with NYHA class III or IV symptoms to those with
NYHA class I or II symptoms. The etiology of heart failure was
defined as a dichotomous variable comparing patients with an
ischemic etiology to those classified as unknown or nonisch-
emic. As there was no statistical evidence of an interaction
between atrial fibrillation and trial involvement (Prevention or
Treatment) on the risk for all-cause mortality, the data from
the SOLVD Prevention and Treatment Trials were analyzed
together, while adjusting for measures of disease severity in the
multivariate analyses.
Categorical data were compared using the chi-squared
statistic and continuous data were compared using the Stu-
dent’s t test assuming unequal variances where appropriate. A
p value #0.05 was considered statistically significant. Kaplan–
Meier survival curves of patients with atrial fibrillation were
compared to those of patients in sinus rhythm using the
log-rank statistic.
Univariate analyses of the relationships of each covariate
with the risk of death, pump-failure death, arrhythmic death
and the composite end point of death of hospitalization for
heart failure were investigated using the Cox-proportional
hazards model. A two-sided, 95% confidence interval (CI) was
constructed around each point estimate of relative risk (RR)
and a p value #0.05 was considered statistically significant.
Multivariate relationships were likewise analyzed using the
Cox-proportional hazards model.
Results
Baseline characteristics. Table 1 displays the baseline
characteristics of patients in sinus rhythm, as compared to
those with atrial fibrillation, on the prerandomization ECG.
Compared to those in sinus rhythm, patients with atrial
fibrillation were older (63 vs. 60 yr; p , 0.001), more likely to
have NYHA class III or IV functional capacity (22% vs. 12%,
p , 0.001) and had a lower mean ejection fraction (26 6 7 vs.
27 6 6, p 5 0.005). Patients with atrial fibrillation were also
more likely to have a history of a stroke than those in sinus
rhythm (11% vs. 6%, p , 0.001). Patients with atrial fibrillation
were less likely to have a history of myocardial infarction (38%
vs. 77%, p , 0.001) and were less likely to be classified with an
ischemic etiology of heart failure (44% vs. 81%, p , 0.001).
The prevalence of prior hypertension (39% vs. 40%) and
diabetes (18% vs. 20%) was not statistically different in the two
groups. Patients with atrial fibrillation more frequently used
anticoagulants (35% vs. 9%), digoxin (81% vs. 30%), diuretics
(59% vs. 39%) and antiarrhythmic drugs (23% vs. 17%) (all p #
0.001) compared to those in sinus rhythm. Patients with atrial
fibrillation were more likely to be randomized to enalapril than
those in sinus rhythm at baseline (55% vs. 50%, p 5 0.02).
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Patients with atrial fibrillation were less likely than patients in
sinus rhythm to use beta-blockers (9% vs. 18%, p , 0.001) and
antiplatelet agents (20% vs. 46%, p , 0.001). The average
resting heart rate was slightly higher in patients with atrial
fibrillation (79 vs. 77 beats/min; p 5 0.001) and a greater
proportion of patients with atrial fibrillation were in the
SOLVD Treatment Trial compared to those in sinus rhythm at
baseline (60% vs. 37%, p , 0.001).
Survival and causes of death. Figure 1 displays the Kaplan–
Meier survival curves for patients who were in atrial fibrillation
and those who were in sinus rhythm at the time of randomiza-
tion into the SOLVD trials. The overall mortality of patients
with atrial fibrillation was greater than those in sinus rhythm
(log-rank p , 0.001). Figure 2 displays the event-free survival
from deaths classified as due to progressive pump failure.
Patients with atrial fibrillation were more likely to die from
progressive pump failure than those in sinus rhythm (log-rank
p , 0.001). Figure 3 displays event-free survival from the
composite end point of death or hospitalization for heart
failure, demonstrating that the patients with atrial fibrillation
were more likely than those in sinus rhythm to experience this
composite end point (log-rank p , 0.001). There was no
difference in survival between patients with atrial fibrillation
and sinus rhythm from deaths classified as arrhythmic (p 5
0.36). In terms of absolute risk, the unadjusted incidence per
100 participant-years of follow-up was greater in the patients
with atrial fibrillation compared to those in sinus rhythm at
baseline for: all-cause mortality (13.1 vs. 8.2, p , 0.001),
pump-failure death (6.4 vs. 3.4, p , 0.001) and the composite
end point of death or hospitalization for heart failure (21 vs.
13.1, p , 0.001), but not arrhythmic death (2.5 vs. 2.2, p 5
0.36).
Table 2 displays the causes of death in patients with atrial
fibrillation and those in sinus rhythm at the time of random-
ization into either the SOLVD Prevention or Treatment Trial.
In both trials, patients with atrial fibrillation had a greater
all-cause mortality and mortality from progressive heart failure
than those in sinus rhythm. There were no significant differ-
ences in either trial between the participants in atrial fibrilla-
tion compared to those in sinus rhythm in the deaths classified
as either arrhythmic or due to myocardial infarction. In the
Prevention Trial, patients with atrial fibrillation had a slight
excess of deaths classified as due to fatal stroke or pulmonary
Figure 2. Kaplan–Meier event-free survival curves for the end point of
deaths due to progressive pump failure. Patients with atrial fibrillation
(n 5 419; solid line) were more likely than those in sinus rhythm (n 5
6,098; broken line) to die from progressive pump failure (log-rank p ,
0.001). The number of patients in each group surviving at each 365-day
interval is displayed.
Table 1. Baseline Characteristics
Atrial Fibrillation
(n 5 419)
Sinus Rhythm
(n 5 6,098) p Value
Age (yr) 63 6 10 60 6 10 ,0.001
Ejection fraction 26 6 7% 27 6 6% 0.005
radionuclide measurement 64% 63% 0.82
Heart rate (beats/min) 79 6 15 77 6 13 0.001
NYHA class III/IV
symptoms
22% 12% ,0.001
Prevention Trial 40% 63% ,0.001
Treatment Trial 60% 37% ,0.001
Randomization to enalapril 55% 50% 0.02
Male gender 86% 86% 0.87
Etiology of heart failure
Ischemic 44% 81% ,0.001
Nonischemic 24% 7% ,0.001
Unknown 32% 12% ,0.001
Prior history of
Diabetes 18% 20% 0.47
Hypertension 40% 39% 0.60
Myocardial infarction 38% 77% ,0.001
Stroke 11% 6% 0.001
Baseline use of
Antiplatelet 20% 46% ,0.001
Anticoagulant 35% 9% ,0.001
Antiarrhythmic drug 23% 17% 0.001
Digoxin 81% 30% ,0.001
Beta-blocker 9% 18% ,0.001
Diuretic 59% 39% ,0.001
NYHA 5 New York Heart Association.
Figure 1. Kaplan–Meier event-free survival curves for the end point of
all-cause mortality comparing those patients with atrial fibrillation
(n 5 419; solid line) and those patients in sinus rhythm (n 5 6,098;
broken line) at baseline. Patients with atrial fibrillation had a de-
creased cumulative survival compared to those with sinus rhythm
(log-rank p , 0.001). The number of patients in each group surviving
at each 365-day interval is displayed.
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embolus (2.4% vs. 0.8%, log-rank p 5 0.02) as well as an excess
of noncardiovascular deaths (4.8% vs. 2.5%, log-rank p 5
0.03).
Univariate analysis. Upon univariate analysis, atrial fibril-
lation was significantly associated with the risk of all-cause
mortality (relative risk [RR] 1.66, 95% CI 1.40 to 1.97, p ,
0.001), death due to progressive pump failure (RR 1.95, 95%
CI 1.53 to 2.51, p , 0.001) as well as the combined end point
of death or hospitalization for heart failure (RR 1.53, 95% CI
1.32 to 1.78, p , 0.001). Atrial fibrillation was not associated
with the risk for an arrhythmic death on univariate analysis
(RR 1.19, 95% CI 0.81 to 1.75, p 5 0.37).
Left ventricular ejection fraction (EF) was strongly associ-
ated with all-cause mortality (RR per 10% decrease in EF 1.75,
95% CI 1.68 to 1.81, p , 0.001). Aspects of the medical history
that were significantly associated with an increased risk of
mortality on univariate analysis included: age, use of antiar-
rhythmics, diabetes, prior hypertension, prior stroke and
NYHA functional class III or IV symptoms. Drug therapy
associated with a reduction in the risk for death included: use
of antiplatelet agents, anticoagulants, beta-blockers and the
study drug enalapril. Medications associated with an increased
risk of mortality on univariate analysis included: diuretics,
digoxin and antiarrhythmic drugs. Gender was not associated
with all-cause mortality on univariate analysis.
Multivariate analysis. Multivariate analyses of the associ-
ation of atrial fibrillation with the risk of all-cause mortality
and death due to progressive pump failure are presented in
Tables 3 and 4, respectively. After adjusting for differences in
the severity of illness, medication use and other potentially
confounding influences, the presence of atrial fibrillation re-
mained independently associated with all-cause mortality (RR
1.34, 95% CI 1.12 to 1.62, p 5 0.002), pump-failure death (RR
1.42, 95% CI 1.09 to 1.85, p 5 0.01), but not sudden death (RR
1.13, 95% CI 0.75 to 1.71, p 5 0.55).
Variables independently associated with the risk of all-
cause mortality in the multivariate model included: age (a 10%
increased risk per 5-yr increase in age, p , 0.001), a decline in
EF (45% increased risk per 10% decrease in EF, p , 0.001),
NYHA class III or IV symptoms (74% increased risk for class
III/IV relative to class I/II, p , 0.001), diabetes (34% increased
risk, p , 0.001), use of any antiarrhythmic drug (28% in-
creased risk, p 5 0.004) and diuretic use (67% increased risk,
p , 0.001). The variables associated with a reduced risk of
death included: use of antiplatelet agents (21% reduction in
risk, p , 0.001), anticoagulants (25% reduction in risk, p ,
Figure 3. Kaplan–Meier event-free survival curves for the composite
end point of death or hospitalization for heart failure. Patients with
atrial fibrillation (n 5 419; solid line) were more likely than those in
sinus rhythm (n 5 6,098; broken line) to die or be hospitalized for
heart failure (log-rank p , 0.001). The number of patients in each
group surviving at each 365-day interval is displayed.
Table 2. Events for Participants in Atrial Fibrillation Compared to
Sinus Rhythm
Prevention Trial Participation
Log-rank
p Value
Atrial
Fibrillation (%)
(n 5 168)
Sinus
Rhythm (%)
(n 5 3,855)
All-cause mortality 20.8 14.7 0.006
Pump-failure death 7.7 4.5 0.02
Arrhythmic death 4.2 4.6 0.99
Myocardial infarction 1.8 2.3 0.85
Fatal Stroke or PE 2.4 0.8 0.02
Noncardiovascular 4.7 2.5 0.03
Treatment Trial Participants
Atrial
Fibrillation (%)
(n 5 251)
Sinus
Rhythm (%)
(n 5 2,243)
Log-rank
p Value
All-cause mortality 43.4 36.9 0.02
Pump-failure death 22.7 18.0 0.03
Arrhythmic death 8.4 8.6 0.91
Myocardial infarction 4.0 4.2 0.95
Fatal Stroke or PE 2.0 1.2 0.24
Noncardiovascular 6.4 4.9 0.21
PE 5 pulmonary embolus.
Table 3. Multivariate Analysis: Variables Significantly Associated
With All-Cause Mortality*
Relative
Risk
95% Confidence
Interval p Value
Age (per 5-yr increase) 1.10 1.08–1.12 ,0.001
Atrial fibrillation 1.34 1.12–1.62 0.002
Ejection fraction (per 10%
decrease)
1.45 1.39–1.50 ,0.001
NYHA class III/IV symptoms† 1.74 1.53–1.97 ,0.001
Diabetes 1.34 1.19–1.51 ,0.001
Prior stroke 1.43 1.20–1.71 ,0.001
Diuretic use 1.67 1.49–1.88 ,0.001
Antiarrhythmic use 1.28 1.14–1.45 0.004
Beta-blocker use 0.79 0.67–0.93 0.005
Anticoagulant use 0.75 0.63–0.89 ,0.001
Antiplatelet agent use 0.79 0.70–0.89 ,0.001
Randomization to enalapril 0.86 0.78–0.95 0.003
*Other variables in the multivariate model which did not remain significantly
associated with outcome included: prior myocardial infarction, history of angina,
history of hypertension, etiology of heart failure and simultaneous use of
antiplatelet and anticoagulant therapy. †Compared to participants with New
York Heart Association (NYHA) class I or class II symptoms.
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0.001), randomization to enalapril (14% reduction in risk, p 5
0.003) and beta-blockers (21% reduction in risk, p 5 0.005).
Although not associated with all-cause mortality on univar-
iate analysis, we did conduct a multivariate analysis that
included gender in the model in addition to all the other
covariates used in the main analysis. On multivariate analysis,
gender was also not independently associated with all-cause
mortality, and atrial fibrillation remained independently asso-
ciated with mortality (RR 1.32, 95% CI 1.10 to 1.59, p 5
0.003).
Analysis limited to patients with atrial fibrillation not
receiving antiarrhythmic drugs. Although we adjusted for the
use of any antiarrhythmic drug in the multivariate model, we
could not adjust by specific antiarrhythmic drug class since
these data were unavailable. We conducted, therefore, a
subanalysis limited to the 321 (77%) participants with atrial
fibrillation who were not receiving any type of antiarrhythmic
drug at the time of randomization into either of the two
SOLVD Trials. The presence of atrial fibrillation in this cohort
was also strongly associated with an increased risk for all-cause
mortality in univariate analysis (RR 1.63, 95% CI 1.34 to 1.98,
p , 0.001). In multivariate analysis, as in the main analysis,
atrial fibrillation remained associated with the risk for all-cause
mortality (RR 1.44, 95% CI 1.17 to 1.78, p , 0.001) as well as
pump-failure death (RR 1.58, 95% CI 1.17 to 1.78, p 5 0.01),
but not sudden death (RR 1.15, p 5 0.57). Likewise, we
conducted an analysis of the patients in atrial fibrillation who
were not using any antiarrhythmic drug and all of whom were
randomized to receive treatment with enalapril (n 5 175). In
this subgroup, patients with atrial fibrillation demonstrated an
increased risk for all-cause mortality (RR 1.45, 95 CI 1.08 to
1.95, p 5 0.01) compared to those in sinus rhythm despite
multivariate adjustment for the same covariates as in the
primary analysis.
Hospitalizations for heart failure. To further address the
hypothesis that atrial fibrillation may accelerate the progres-
sion of heart failure, we examined the association of atrial
fibrillation with the composite end point of death or hospital-
ization for worsening heart failure. The rate of death or
hospitalization for heart failure in patients with atrial fibrilla-
tion was 21.0 compared to 13.1 events per 100 participant-years
of follow-up for patients in sinus rhythm (p , 0.001). Atrial
fibrillation was associated with the composite end point of
death or hospitalization for heart failure in univariate analysis
(RR 1.44, 95% CI 1.24 to 1.67, p , 0.001) as well as multi-
variate analysis (RR 1.21, 95% CI 1.03 to 1.42, p 5 0.02), despite
adjusting for the same covariates as the primary analysis.
Use of calcium-channel blockers. Data on the use of
calcium-channel blockers were available for 5,116 patients, of
whom 4,783 were in sinus rhythm and 333 in atrial fibrillation
at the time of randomization. Within these patients, the
participants with atrial fibrillation were less likely than those in
sinus rhythm to use a calcium-channel blocker (29% vs. 44%,
p , 0.001). However, calcium-channel blocker use was not
independently associated with the risk for mortality. The
inclusion of calcium-channel blocker use in the multivariate
model had no effect on the association of atrial fibrillation with
mortality (RR 1.41, 95% CI 1.16 to 1.71, p 5 0.001).
Influence of heart rate. The mean resting heart rate at
baseline was slightly greater in the participants with atrial
fibrillation compared to those in sinus rhythm (79 6 15 vs.
77 6 13 beats/min; p 5 0.002). When we adjusted for the
baseline resting heart rate for each participant in the multivar-
iate model, atrial fibrillation remained independently associ-
ated with all-cause mortality (RR 1.34, 95% CI 1.12 to 1.62,
p 5 0.002), pump-failure death (RR 1.41, 95% CI 1.08 to 1.85,
p 5 0.01) and the combined end point of death or hospital-
ization for heart failure (RR 1.21, 95% CI 1.03 to 1.42, p 5
0.02). The median heart rate for the patients with atrial
fibrillation was 79 beats/min; 75% of the patients with atrial
fibrillation had a baseline resting heart rate #88 beats/min.
When we analyzed the influence of atrial fibrillation on
prognosis in the patients (n 5 216) with atrial fibrillation
whose baseline heart rate was below the median value, atrial
fibrillation was associated with an increased risk for all-cause
mortality (RR 1.60, 95% CI 1.23 to 2.07, p , 0.001), pump-
failure death (RR 1.92, 95% CI 1.30 to 2.84, p 5 0.001) and the
composite end point of death or hospitalization for heart
failure (RR 1.42, 95% CI 1.31 to 1.79, p 5 0.003).
Discussion
The present analysis, although retrospective, has the
strength of including a large number of patients with atrial
fibrillation (n 5 419) and mild to moderate heart failure with
substantial follow-up time (33.4 6 14.3 months). The results of
this study suggest that the presence of atrial fibrillation in
patients with asymptomatic and symptomatic left ventricular
systolic dysfunction is independently associated with an in-
creased risk for all-cause mortality. This appears to be largely
Table 4. Multivariate Analysis: Variables Significantly Associated
With Pump Failure Death*
Relative
Risk
95% Confidence
Interval p Value
Age (per 5-yr increase) 1.11 1.08–1.12 ,0.001
Atrial fibrillation 1.42 1.09–1.85 0.01
Ejection fraction (per 10%
decrease)
1.63 1.53–1.73 ,0.001
NYHA class III/IV symptoms† 2.41 2.02–2.88 ,0.001
Diabetes 1.41 1.18–1.68 ,0.001
Prior stroke 1.35 1.02–1.77 0.03
Diuretic use 1.98 1.64–2.40 ,0.001
Antiarrhythmic use 1.42 1.19–1.71 ,0.001
Beta-blocker use 0.75 0.56–0.99 0.04
Anticoagulant use 0.71 0.55–0.93 0.005
Randomization to enalapril 0.80 0.68–0.93 0.005
*Other variables in the multivariate model which did not remain significantly
associated with outcome included: prior myocardial infarction, history of angina,
history of hypertension, etiology of heart failure, use of antiplatelet agents and
simultaneous use of antiplatelet and anticoagulant therapy. †Compared to
participants with New York Heart Association (NYHA) class I or class II
symptoms.
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explained by an increased risk for death due to progressive
heart failure. The association of atrial fibrillation with death
due to progressive heart failure, as well as the composite end
point of death or hospitalization for worsening heart failure,
supports our hypothesis that atrial fibrillation may be associ-
ated with progression of left ventricular systolic dysfunction. In
contrast to previous data (2), however, atrial fibrillation was
not associated with an increased risk for an arrhythmic death.
Comparison to previous studies. Middlekauff et al. (2)
retrospectively studied 390 consecutive patients that were
referred for an evaluation for cardiac transplantation, 75 of
whom had either chronic or paroxysmal atrial fibrillation. In
contrast to the present study, atrial fibrillation was indepen-
dently associated with an increase in mortality due to an
increased risk of sudden, unexpected death. Stevenson et al.
(11) subsequently reported that in patients with severe heart
failure, the prognosis for those with atrial fibrillation appears
to be improving. The improved mortality in these patients
appeared to parallel an increased use of both amiodarone and
angiotensin-converting enzyme inhibitors and a decreased use
of Vaughan–Williams class I antiarrhythmic drugs in the
patients with severe heart failure and atrial fibrillation. The
authors speculated that the association of atrial fibrillation
with an increased risk for sudden death, as demonstrated in
previous studies (2), may have reflected the confounding
influence from class I antiarrhythmic agents which themselves
may have increased the mortality in these patients by the
mechanism of proarrhythmia. The population of patients in
these studies included a significantly greater proportion with
severe (NYHA class IV) heart failure compared to the
SOLVD Trials. The increased mortality risk associated with
atrial fibrillation in the analysis from Middlekauff et al. (2) was
limited to sudden death. However, the present analysis of the
SOLVD Trials demonstrates that atrial fibrillation is associ-
ated with an increased mortality risk largely explained by an
increased risk for death from pump failure. Our data also differ
in that they demonstrate no association with the risk of
arrhythmic death. Moreover, the adverse prognostic impact of
atrial fibrillation in the SOLVD Trials was apparent even in
the patients with atrial fibrillation reporting no use of antiar-
rhythmic drugs at baseline and subsequently randomized to
receive treatment with enalapril.
Carson et al. (1) studied the impact of atrial fibrillation in
heart failure patients entered into the Holter substudy of
the Vasodilator-Heart Failure (V-HeFT) I and II Trials: a
total of 99 patients with atrial fibrillation in V-HeFT I and
107 patients with atrial fibrillation in V-HeFT II. These
trials compared hydralazine-isosorbide dinitrate combina-
tion therapy to placebo (Ve-Heft I) and hydralazine-
isosorbide dinitrate combination therapy with enalapril (Ve-
Heft II) in patients with mild to moderate heart failure. The
survival of patients with atrial fibrillation, whether chronic
or paroxysmal, was not statistically different from that in
patients in sinus rhythm in either Ve-HeFT study. More-
over, atrial fibrillation, whether chronic or paroxysmal, was
not associated with all-cause mortality or sudden death on
either univariate or multivariate analysis.
The V-HeFT studies, in contrast to the present analysis,
identified patients with atrial fibrillation using periodic Holter
monitoring. They were able, therefore, to categorize atrial
fibrillation as either chronic or paroxysmal. The patients with
atrial fibrillation in the SOLVD studies had evidence of more
severe underlying disease compared to those in sinus rhythm.
Baseline differences in the severity of heart failure between
those participants with atrial fibrillation compared to those
with sinus rhythm were less apparent in the Ve-HeFT studies.
Nonetheless, despite adjusting for the differences in disease
severity, atrial fibrillation remained independently associated
with all-cause mortality, death from progressive pump failure
and the combined end point of death or hospitalization for
heart failure in the present analysis. We cannot further account
for the different conclusions between the present study and
that of the V-HeFT investigators.
Possible mechanisms whereby atrial fibrillation may ad-
versely influence heart failure. The chronically fast heart rate
that may result from atrial fibrillation may result in left
ventricular dysfunction and improve with conversion back to
sinus rhythm (15–17). It is also likely that in patients with left
ventricular dysfunction resulting from other primary etiologies,
chronically rapid heart rates resulting from atrial fibrillation
might exacerbate the underlying degree of left ventricular
dysfunction. The increased proportion of atrial fibrillation
patients with nonischemic left ventricular dysfunction might
suggest that some of the SOLVD patients with atrial fibrilla-
tion had tachycardia-induced cardiomyopathy (17). However,
it is unlikely that the adverse prognostic impact of atrial
fibrillation was limited to these patients. For example, the
average resting heart rate for the patients with atrial fibrilla-
tion, although greater than those in sinus, was only 79 beats/
min, and 75% of the patients with atrial fibrillation had a
resting heart rate #88 beats/min. When we adjusted for the
resting heart rate in the multivariate model, there was no
change in the magnitude of the independent association of
atrial fibrillation with the risk of mortality, death due to pump
failure, or the composite end point of death or hospitalization
for heart failure. Moreover, the group of patients with atrial
fibrillation whose resting heart rate was below the median
value for the atrial fibrillation group (#78 beats/min) remained
at significantly increased risk for these endpoints.
Recent data suggest that the variation in ventricular cycle
lengths (R-R intervals) resulting from atrial fibrillation may
adversely affect ventricular function and the hemodynamic
status independently from the effect of atrial fibrillation upon
the ventricular rate. In a canine model, Naito et al. (18)
demonstrated that the persistent irregularity in ventricular
cycle lengths, due to atrial fibrillation, leads to a significant
decline in cardiac output independent of heart rate. Clark et al.
(6) recently demonstrated similar results in humans.
Other mechanisms of hemodynamic deterioration include
the loss of atrial-ventricular synchrony which reduces end-
diastolic pressure and volume in both ventricles and may result
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in a reduction in stroke volume, an increase in the mean
diastolic pressure in the atria, ventricular-valvular regurgita-
tion and a reduced time interval for passive diastolic filling
(18–21).
Atrial fibrillation may have an adverse effect on patients
with heart failure due to the adverse effects of drugs commonly
used in these patients. For example, calcium-channel blockers
are used on occasion to assist in rate control, despite the
negative inotropic effects, in patients with atrial fibrillation and
heart failure. This might exacerbate symptoms of heart failure,
leading to a hospitalization for worsening heart failure. Some
case-control studies have suggested that calcium-channel
blockers may be associated with an increase in mortality in
patients with coronary disease and left ventricular dysfunction
(22,23). Antiarrhythmic drugs, in particular the class I antiar-
rhythmic agents, may result in fatal proarrhythmia in this
population (11). In the present analysis, however, even after
adjusting for the differences in medication use between those
participants with atrial fibrillation and those in sinus rhythm,
atrial fibrillation remained independently associated with the
risk for all-cause mortality, pump-failure death and the com-
bined end point of death or hospitalization for heart failure.
Patients with atrial fibrillation are at an increased risk for
thromboembolic events compared to patients in sinus rhythm,
in which the incidence of thromboembolic events is low despite
severe left ventricular dysfunction (24). In the present study,
however, the differences in deaths from fatal strokes or pul-
monary emboli accounted for a small proportion of the excess
mortality in patients with atrial fibrillation compared to those
in sinus rhythm.
The association of atrial fibrillation with all-cause mortality
and progressive pump failure may reflect the fact that the
presence of atrial fibrillation is a marker for more severe
underlying disease. Measures of EF and functional capacity as
measured by the NYHA classification scheme, although well-
documented prognostic markers in heart failure, are relatively
crude measures of the underlying disease process. It is possible
that the presence of atrial fibrillation merely identifies patients
with other unmeasured differences in disease severity that
themselves influence survival in this population.
Limitations
This is a retrospective analysis of the SOLVD Trials and is
therefore subject to the limitations of all retrospective analy-
ses. One obvious concern is that the association of atrial
fibrillation with all-cause mortality in the present analysis is
explained by the fact that the patients with atrial fibrillation
had more severe underlying disease than those in sinus rhythm.
We made every effort, however, to adjust for these differences
in the multivariate model. Nonetheless, despite adjusting for
these differences, atrial fibrillation remained independently
associated with all-cause mortality, death due to progressive
pump failure and the composite end point of death or hospi-
talization for heart failure. We acknowledge, however, the
possibility for residual confounding from both measured and
unmeasured variables.
There was a particular concern about the reported use of
antiarrhythmic therapy since we lacked information about the
specific drugs used. We conducted, therefore, a subanalysis
which was limited to those patients with atrial fibrillation
reporting no use of any antiarrhythmic drugs. When limited to
this cohort, the association between atrial fibrillation and the
risk for all-cause mortality and death due to progressive pump
failure persisted.
It is important to acknowledge that the classification of
deaths according to etiology is imprecise in these populations
(25). Those deaths classified by the SOLVD investigators as
“arrhythmic with no antecedent heart failure” may have re-
sulted from fatal myocardial infarctions, ventricular tachyar-
rhythmias, bradyarrhythmias, fatal pulmonary emboli or fatal
strokes. To increase the specificity of our definition of an
arrhythmic death, only those deaths that were classified as
“sudden with no antecedent evidence of worsening heart
failure” by the SOLVD investigators were included. It is likely
that misclassification of the causes of death existed.
The qualifying EFs in the majority of patients were ob-
tained using radionuclide angiography. This technique can
underestimate the EF in patients with atrial fibrillation due to
gating difficulties arising from the irregular sequences of
ventricular activation (26). Although we adjusted for resting
heart rate, we did not have data on the ventricular response to
exercise. It is possible that the patients with atrial fibrillation,
although demonstrating an acceptable average heart rate at
rest, may have had poor rate control with activity.
A final concern is that the data for the present analysis were
obtained in each participant at the time of randomization. It is
likely that some of the patients in sinus rhythm later developed
atrial fibrillation. However, assuming that this were the case
and that there was an association of atrial fibrillation with
mortality, it is expected that the bias would be toward finding
no association of atrial fibrillation with the outcomes of
interest. Likewise, patients in atrial fibrillation at baseline may
have later converted to sinus rhythm. If we assume that
paroxysmal atrial fibrillation is less likely to have adverse
effects in heart failure than chronic atrial fibrillation, we would
once again expect that this would make it more difficult to
demonstrate an association of atrial fibrillation with the out-
comes of interest. Medication use was also assessed at baseline
and likely changed during follow-up. However, it seems un-
likely that changes in medication during the course of the
SOLVD Trials introduced a systematic bias into the present
analysis.
Clinical implications. The optimal treatment strategy for
atrial fibrillation, in particular those with significant left ven-
tricular systolic dysfunction, is yet to be elucidated. Although
rate control appears to be beneficial (15–17), it can be difficult
in patients with heart failure to achieve adequate rate control
during activity. The choice of which agents to use in addition to
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digoxin for improving rate control is complicated in this
population. The use of beta-blockers, specifically the third-
generation compounds, appears to be promising in patients
with mild to moderate heart failure (27), but a benefit for
patients in atrial fibrillation and heart failure has not been
specifically demonstrated. Regarding the use of antiarrhythmic
drug therapy to maintain or restore sinus rhythm, amiodarone
appears to be safe in this population (28). In addition to
helping restore or maintain sinus rhythm, amiodarone can
function to control the ventricular response to atrial fibrilla-
tion. Other antiarrhythmic drugs must be used cautiously,
however, because of concerns for an increase in mortality due
to fatal proarrhythmia (11). Other treatment modalities exist
such as ablation of the atrial-ventricular node and insertion of
a rate-responsive ventricular pacemaker. This has been dem-
onstrated to improve ventricular function in patients with atrial
fibrillation and rapid ventricular heart rates (29). Moreover, as
previously mentioned, the irregularity in the ventricular cycle-
length (R-R intervals) resulting from atrial fibrillation can
adversely influence hemodynamic parameters independent of
the heart rate (18). This suggests that atrioventricular nodal
ablation and ventricular pacing might confer long-term hemo-
dynamic benefits by a mechanism that is independent of the
improvement attributed to improved rate control in patients
with heart failure and atrial fibrillation.
The ongoing National Heart, Lung and Blood Institute-
sponsored AFFIRM Trial (Atrial Fibrillation Follow-up Inves-
tigation of Rhythm Management) may help to clarify some of
these concerns (30). This trial is comparing two strategies used
to treat patients with atrial fibrillation: rate-control and anti-
coagulation vs. an aggressive attempt to restore sinus rhythm.
Importantly, this trial is including patients with left ventricular
dysfunction and heart failure and hopefully will provide im-
portant data to help identify an optimal treatment strategy in
these patients.
Conclusions. In patients with asymptomatic and symptom-
atic left ventricular systolic dysfunction, atrial fibrillation is
independently associated with an increased risk for death,
largely explained by an increased risk for progressive pump-
failure death. The presence of atrial fibrillation in patients with
mild to moderate heart failure, therefore, appears to identify
patients that deserve particular attention and careful manage-
ment. Even if the major adverse prognostic impact of atrial
fibrillation is related to the severity of the underlying condi-
tions rather than the presence of atrial fibrillation itself, these
data suggest that the severity exceeds that evident from other
clinical information. These patients then appear to warrant
particular vigilance with regard to the adequacy of their
medical regimen and the frequency of follow-up.
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